Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12675963 | 0.71 | KDM4E (0.32) | — | |
| SCHEMBL12537401 | 0.65 | TYMS (0.33) | — | |
| SCHEMBL17925340 | 0.65 | UCHL1 (0.30) | GSK3B | |
| SCHEMBL11758270 | 0.62 | ALOX15 (0.36) | — | |
| SCHEMBL6851025 | 0.62 | GSK3B (0.44) | GSK3B | |
| SCHEMBL13552154 | 0.60 | — | — | |
| SCHEMBL9587810 | 0.58 | GSK3B (0.37) | GSK3B | |
| SCHEMBL5416241 | 0.56 | GSK3B (0.35) | GSK3B | |
| SCHEMBL710762 | 0.56 | — | — | |
| SCHEMBL708902 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023211850-A1 | KCNT1 INHIBITORS COMPRISING AN ISOXAZOLE OR OXADIAZOLE CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-11-02 | — | — | WO | disclosed |
| CN-114641337-A | CEREBLON E3 ligase inhibitors | 密歇根大学董事会 | 2022-06-17 | — | — | CN | disclosed |
| EP-3318253-A1 | COMPOSITIONS COMPRISING WNT INHIBITORS FOR TREATING CANCER | Schmidt-Wolf, Ingo (DE) | 2018-05-09 | — | — | EP | disclosed |
| WO-2015181135-A1 | SKIN CANCER TREATMENT | AVEXXIN AS (NO) | 2015-12-03 | — | — | WO | disclosed |
| EP-1861401-B1 | 7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES | JANSSEN PHARMACEUTICA NV (BE) | 2015-11-18 | — | — | EP | disclosed |
| EP-2644641-B1 | Polyetherimides, methods of manufacture, and articles formed therefrom | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2015-11-04 | — | — | EP | disclosed |
| EP-2610257-A1 | DIIMIDATED DERIVATIVE OF BERBAMINE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Hangzhou Bensheng Pharmaceutical Co., Ltd. (CN) | 2013-07-03 | — | — | EP | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-1457482-B9 | Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein | JAPAN SCIENCE & TECH AGENCY (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-1457482-B1 | Stable isotope-labeled amino acid, method of integrating the same into target protein, method of NMR structural analysis of protein | JAPAN SCIENCE & TECH AGENCY (JP) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010055887-A1 | NOVEL SULFONIUM SALT, METHOD FOR PRODUCING SAME AND USE OF SAME | 国立大学法人佐賀大学 (JP) | 2010-05-20 | — | — | WO | disclosed |
| US-7244847-B2 | Benzimidazole compounds | ISIS PHARMACEUTICALS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | GSK3B 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.